AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio
AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments for rare endocrine diseases, in a deal ... Read More
French biotech company Amolyt Pharma Series C round fetches $138m
Amolyt Pharma, a France-based clinical-stage biotechnology company, has secured €130 million (around $138 million) from a Series C equity financing round led by Sofinnova Partners ... Read More